Geron Corporation Reports Q2 2026 Financial Results with $16.7M Net Loss and 17% Revenue Growth

Geron Corporation reported its financial results for the second quarter of 2026, revealing a net loss of $16.7 million, slightly higher than the $16.4 million loss recorded in the same period of 2025. For the first half of 2026, the company’s net loss was $20.3 million, a significant improvement compared to a loss of $36.2 million in the first half of 2025. The company’s total revenues for the second quarter increased by 17% to $57.5 million, driven primarily by product revenue from RYTELO, which amounted to $57.5 million, up from $49.0 million in the prior year. For the six months ended June 30, 2026, total revenues reached $109.3 million, a 23% increase from $88.6 million in the same period of 2025.

The increase in product revenue was attributed to higher sales volumes and a modest increase in selling prices, although this was partially offset by increased gross-to-net adjustments, which rose to 20.7% of gross product revenue in the second quarter. This increase was primarily due to a higher proportion of sales made under governmental managed-care pricing programs and group purchasing organizations. The company noted that three customers accounted for approximately 96% of its gross accounts receivable as of June 30, 2026, indicating a concentrated customer base.

Geron has been actively working on the commercialization of RYTELO, which was launched in the U.S. in June 2024 following FDA approval. The company is also preparing for the planned commercialization of RYTELO in select European markets in 2026 after receiving marketing authorization from the European Commission in March 2025. To facilitate patient access outside the U.S., Geron has partnered with Tanner Pharma for distribution through Named Patient Programs. The company is also advancing its clinical trials for imetelstat, with ongoing studies aimed at treating various hematologic malignancies.

Operationally, Geron has undergone significant changes, including a workforce reduction in December 2025, which resulted in approximately $17 million in restructuring charges. The company reported a decrease in its employee headcount, which contributed to lower general and administrative expenses. As of June 30, 2026, Geron had approximately $326.9 million in cash, cash equivalents, restricted cash, and marketable securities, down from $401.1 million at the end of 2025. The company anticipates that its existing cash resources, along with projected revenues from RYTELO, will be sufficient to fund its operations for the foreseeable future.

Looking ahead, Geron remains focused on the successful commercialization of RYTELO and expanding its indications for use. The company acknowledges the inherent uncertainties in drug development and commercialization, including potential regulatory challenges and market acceptance. Geron’s future financial performance will largely depend on its ability to generate meaningful revenue from RYTELO sales and manage its operational costs effectively. The company is also exploring additional funding options to support its ongoing development and commercialization efforts.